AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10334415
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg twice daily for 4 weeks)
Trial: 25587645
Drug: 50 mg/d
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/d lisdexamfetamine
Trial: 25587645
Drug: 70 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg/d lisdexamfetamine
Trial: 25587645
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d lisdexamfetamine
Trial: 24101042
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation intensity‐modulated radiation therapy (CIMRT) - 76 Gy in 38 fractions at 2.0 Gy per fraction
Trial: 21744190
Drug: Application of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of stickers and criteria for switch to oral antimicrobial therapy to the drug chart in the study group post-intervention
Trial: 21744190
Drug: Conventional practice
RxNorm normalized name: Practical Alchemy Purify and Protect Duo KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional practice of clinical pharmacists reviewing drug charts and contacting prescribers to discuss a switch to an oral antimicrobial in the control group
Trial: 23500218
Drug: Adenosine administration
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine administration
Trial: 11738309
Drug: Metoprolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (0.1 mg/kg)
Trial: 11738309
Drug: Sotalol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (1.0 mg/kg)
Trial: 7905095
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori eradication treatment (HET)
Trial: 2721334
Drug: Naltrexone 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 2.0 mg/kg
Trial: 29605395
Drug: Prophylactic dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dextrose gel (0.5 mL/kg) rubbed into the buccal mucosa
Trial: 23076338
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss intervention (26-week multidisciplinary treatment programme)
Trial: 20858829
Drug: Protocol C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol C (15 HU and 600 mg I/kg)
Trial: 20858829
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (12 HU and 521 mg I/kg)
Trial: 20858829
Drug: Protocols B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocols B and C (15 HU and 521 mg I/kg; 15 HU and 600 mg I/kg)
Trial: 20858829
Drug: Protocols A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocols A and C (12 HU and 521 mg I/kg; 15 HU and 600 mg I/kg)
Trial: 18479175
Drug: Esomeprazole 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 80 mg/day
Trial: 18479175
Drug: Pantoprazole 80
RxNorm normalized name: pantoprazole 80 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 80 mg/day
Trial: 15845680
Drug: Target-Controlled Infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-Controlled Infusion (TCI) of Propofol
Trial: 15845680
Drug: Manually Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually Controlled (MAN) Propofol Infusion
Trial: 2239143
Drug: Controlled-release carbamazepine
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release carbamazepine (CR CBZ)
Trial: 402795
Drug: Thyrotropin-Releasing Hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-Releasing Hormone (TRH) administered orally, 20 mg three times a day for 3 weeks (double-blind study)
Trial: 402795
Drug: Thyrotropin-Releasing Hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-Releasing Hormone (TRH) administered orally, 20 mg four times a day for 2 weeks (open controlled study)
Trial: 402795
Drug: Thyrotropin-Releasing Hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-Releasing Hormone (TRH) administered orally
Trial: 31026734
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of public settings used for drug consumption (shooting gallery, crack house, abandoned building, public bathroom, outside)
Trial: 28234790
Drug: Levosimendan 0.2 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 0.2 μg/kg/min
Trial: 28234790
Drug: Dobutamine 5 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine 5 μg/kg/min
Trial: 15295221
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of sunflower seed oil 3 times daily
Trial: 3181323
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated measles vaccine developed in chick embryo cells
Trial: 3181323
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated measles vaccines developed in human diploid cells (HDC)
Trial: 3181323
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated measles vaccine developed in baby calf kidney cells
Trial: 436923
Drug: Practolol 4
RxNorm normalized name: (±)-practolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol 4 mg/kg
Trial: 436923
Drug: Propranolol 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.2 mg/kg
Trial: 31648187
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of testosterone
Trial: 25466317
Drug: Protocolized sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized sedation plus daily interruption (DI)
Trial: 25466317
Drug: Daily interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interruption (DI)
Trial: 18198639
Drug: Tetramethylpyrazine (TMP)
RxNorm normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetramethylpyrazine (TMP) treatment for 14 days
Trial: 15990619
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for ocular hypertension with NNT of 20 for average patients, NNT of 6 for those with IOP > or =26 mm Hg.
Trial: 15990619
Drug: Targeting higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeting higher risk patients for treatment.
Trial: 15990619
Drug: Collaborative initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Collaborative initial glaucoma treatment study (CIGTS) justifying primary surgery.
Trial: 8903978
Drug: Topicaina spray
RxNorm normalized name: Topicaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topicaina spray (benzocaine butyl aminobenzoate, amethocaine, butacaine)
Trial: 1978605
Drug: tubocurarine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tubocurarine 0.05 mg/kg (group 2)
Trial: 1978605
Drug: vecuronium 0.006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.006 mg/kg (group 3)
Trial: 1978605
Drug: midazolam 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.025 mg/kg (group 4)
Trial: 1978605
Drug: vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.1 mg/kg (group 5)
Trial: 21521283
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (5 or 10 g/daily) plus rhGH (0, 3 or 5 μg/kg/day)
Trial: 16702472
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE; 0.625 mg; n=5310)
Trial: 11498833
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy to the ipsilateral breast
Trial: 11498833
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) after lumpectomy and radiation therapy
Trial: 9515223
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil 100 mg preprandial
Trial: 9515223
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil 200 mg preprandial
Trial: 9515223
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil 300 mg preprandial
Trial: 9515223
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil 200 mg postprandial
Trial: 9515223
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil 200 mg every 12 hours for 7 days
Trial: 8427430
Drug: Metoclopramide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide + Ibuprofen
Trial: 3679703
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg elemental zinc/day
Trial: 3679703
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg elemental zinc/day
Trial: 3679703
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg elemental zinc/day
Trial: 29429948
Drug: VR-CBT (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VR-CBT (16 individual therapy sessions, each 1 hour long)
Trial: 29429948
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control (treatment as usual)
Trial: 27222342
Drug: Caffeine solution
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine solution during 180 min of stationary cycling
Trial: 24299727
Drug: G‐CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (10 μg/kg/d) intravenously for 5 consecutive days
Trial: 24299727
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no G‐CSF administration)
Trial: 24354675
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (KRG) 500 mg, six capsules twice a day for eight weeks
Trial: 24354675
Drug: Placebo, six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, six capsules twice a day for eight weeks
Trial: 20846227
Drug: Antenatal pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal pelvic floor muscle exercises (4 sessions of taught training during pregnancy and 8-12 maximal contractions twice daily at home)
Trial: 2033138
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 0.1% cream, applied once daily
Trial: 2033138
Drug: Hydrocortisone 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1.0% cream, applied twice daily
Trial: 7012247
Drug: Single-dose ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ampicillin (100 mg/kg)
Trial: 7012247
Drug: Five-day multiple-dose
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day multiple-dose ampicillin (100 mg/kg per 24 hr)
Trial: 25395689
Drug: Intramuscular droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular droperidol (10 mg)
Trial: 25395689
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol (10 mg)
Trial: 22986010
Drug: Having a
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Having a full-time job and shorter abstinence time before treatment (until 7 days)
Trial: 12941676
Drug: 0.25 mg/d
RxNorm normalized name: fluoride 0.25 mg/drop oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/d of micronized 17beta-estradiol (n = 83)
Trial: 11899388
Drug: Docetaxel 60-100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60-100 mg/m2 given as a 1-hour infusion every 3 weeks
Trial: 11899388
Drug: Taxanes as
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxanes as a component of first-line therapy
Trial: 8888110
Drug: Desipramine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (200 mg/day for 6 weeks)
Trial: 1473367
Drug: Ciprofloxacin (CIP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CIP; 200‐300 mg, i.v. b.i.d.) + vancomycin (VAN; 0.5‐1 g, i.v. b.i.d.)
Trial: 1473367
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g, i.v. t.i.d.) + gentamicin (1 mg/kg, i.v. t.i.d.)
Trial: 31630465
Drug: Bilateral ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound-guided erector spinae plane block using 0.3 mL/kg bupivacaine 0.25% (on each side) with a maximum dose of 2 mg/kg
Trial: 31630465
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received general anesthesia with bilateral sham erector spinae plane block using 0.3 mL/kg normal saline on each side
Trial: 28921547
Drug: 6% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydrogen peroxide (HP) for 1.5 hours daily for 21 days
Trial: 28921547
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide (CP) for 4 hours daily for 21 days
Trial: 25071901
Drug: rebamipide 100
RxNorm normalized name: Rebamipide 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rebamipide 100 mg three times per day
Trial: 25071901
Drug: misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: misoprostol 200 μg three times per day
Trial: 22916885
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk supplemented with Bifidobacterium lactis Bi‐07 and Lactobacillus acidophilus NCFM, and isomaltooligosaccharide, 480 g/d for 2 weeks
Trial: 10543292
Drug: Inhaled Mannitol
RxNorm normalized name: mannitol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Mannitol (300 mg)
Trial: 217789
Drug: Premarin Intravenous
RxNorm normalized name: Premarin Intravenous
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premarin Intravenous
Trial: 31639016
Drug: Comprehensive health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive health program (medical exercise therapy and lifestyle coaching)
Trial: 22516427
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (aspirin 325 mg daily plus clopidogrel 75 mg daily)
Trial: 22516427
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (aspirin 325 mg daily plus placebo)
Trial: 16304567
Drug: Vibro-ejaculation weekly
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibro-ejaculation weekly for 3 months (study group)
Trial: 10732934
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg/d) and pyrazinamide (20 mg/kg per day) for 2 months
Trial: 10732934
Drug: Isoniazid (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (300 mg/d) for 12 months
Trial: 3881228
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg, single oral dose)
Trial: 27598552
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pain education, specific exercises, and graded physical activity training
Trial: 24988555
Drug: Epidural injections
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injections of glucocorticoids plus lidocaine
Trial: 22162540
Drug: Trimetazidine 35-mg
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 35-mg MR tablets in fasting state
Trial: 22162540
Drug: Trimetazidine 35-mg
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 35-mg MR tablets in fed state
Trial: 22162540
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation in fasting state
Trial: 22162540
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation in fed state
Trial: 12153550
Drug: Lisinopril (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (dosage not specified)
Trial: 11468536
Drug: Tacrolimus, corticosteroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus, corticosteroids, and 1 g of MMF daily (MMF-1 g group, n=79)
Trial: 11468536
Drug: Tacrolimus, corticosteroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus, corticosteroids, and 2 g of MMF daily (MMF-2 g group, n=71)
Trial: 9780474
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 5 mg i.m. weekly for 24 months
Trial: 3145585
Drug: Bretschneider cardioplegic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretschneider cardioplegic HTK solution (group I)
Trial: 3145585
Drug: St. Thomas
RxNorm normalized name: St. Thomas lidpod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. Thomas cardioplegic solution (group II)
Trial: 23554353
Drug: Insulin stimulation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin stimulation in BAT
Trial: 10808206
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg/day p. o. or i.v.)
Trial: 10808206
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.2 mg/kg/day i.v.)
Trial: 8928757
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor I (IGF-I, 10 micrograms.kg-1.h-1 sc) for 3 days
Trial: 1481646
Drug: Lisuride (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisuride (1.3 mg mean daily dose, range 0.2-2.4 mg)
Trial: 1481646
Drug: Bromocriptine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (15 mg mean daily dose, range 3.75-30.0 mg)
Trial: 1481646
Drug: Control (levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (levodopa and anticholinergic treatment unchanged)
Trial: 16371612
Drug: Midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.5 mg.kg‐1 mixed with acetaminophen suspension
Trial: 16371612
Drug: Acetaminophen alone
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen alone (Control)
Trial: 14556543
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg per day for 8 weeks
Trial: 14556543
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg per day for 8 weeks
Trial: 11524467
Drug: 0.10 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 mg/day of 17 beta‐estradiol by skin patch
Trial: 8390287
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) therapy
Trial: 29855175
Drug: ABT-122 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 (120 or 240 mg every week)
Trial: 29855175
Drug: ABT-122 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 (120 mg every week)